Two of the most formative experiences I gained working as the commercial person within pharmaceutical development teams involved the inability to predict either the absence of patients or the absence of a viable market for products under development.
Stock Watch: When Development Goes Too Far
Beware R&D Organizations With Unfettered Access To Clinical Trial Budgets
R&D managers can sometimes drive a drug’s development despite evidence of its unviability. This has recently resulted in a scramble to adjust in-progress trial protocol and post-approval cost-effectiveness concerns.
More from Stock Watch
More from Business
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.